{"id":66963,"date":"2026-06-01T15:00:26","date_gmt":"2026-06-01T07:00:26","guid":{"rendered":"https:\/\/flcube.com\/?p=66963"},"modified":"2026-06-01T15:00:28","modified_gmt":"2026-06-01T07:00:28","slug":"peijia-medical-secures-exclusive-china-distribution-rights-for-b-brauns-sequent-please-cis-intracranial-drug-coated-balloon","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66963","title":{"rendered":"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun&#8217;s SeQuent Please CIS Intracranial Drug-Coated Balloon"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Peijia Medical Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/9996:HKG\">HKG: 9996<\/a>)<\/strong> announced an exclusive distribution agreement with <strong>B. Braun Melsungen AG<\/strong> for the <strong>SeQuent Please CIS<\/strong>, a <strong>paclitaxel drug-coated intracranial balloon dilatation catheter<\/strong>, in mainland China. The partnership grants Peijia exclusive rights to commercialize B. Braun&#8217;s innovative &#8220;<strong>no-implant<\/strong>&#8221; therapy for intracranial vascular diseases, leveraging B. Braun&#8217;s established <strong>drug-coated balloon (DCB) technology<\/strong> to address the significant unmet need in China&#8217;s cerebrovascular intervention market. The product has been filed for marketing approval in China and is specifically engineered for the <strong>slender and tortuous anatomy of intracranial vessels<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-partnership-details\" class=\"wp-block-heading\">Partnership Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Peijia Medical Ltd. (HKG: 9996) and B. Braun Melsungen AG<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SeQuent Please CIS \u2013 paclitaxel drug-coated intracranial balloon<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Exclusive distribution rights for mainland China<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>B. Braun&#8217;s established drug-coated balloon (DCB) technology<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Marketing application filed with NMPA<\/td><\/tr><tr><td><strong>Therapeutic Approach<\/strong><\/td><td>&#8220;No-implant&#8221; treatment for intracranial vascular diseases<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>01 Jun 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-clinical-innovation\" class=\"wp-block-heading\">Product Profile &amp; Clinical Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action<\/strong>: Precisely releases <strong>paclitaxel<\/strong> (anti-proliferative drug) onto diseased vessel walls during mechanical dilation of target lesions<\/li>\n\n\n\n<li><strong>Primary Benefit<\/strong>: Effectively <strong>inhibits intimal hyperplasia<\/strong> and reduces long-term risk of <strong>restenosis<\/strong><\/li>\n\n\n\n<li><strong>Anatomical Optimization<\/strong>: Specifically designed to accommodate the <strong>slender and tortuous characteristics<\/strong> of intracranial vessels<\/li>\n\n\n\n<li><strong>Therapeutic Paradigm<\/strong>: Provides innovative &#8220;<strong>no-implant<\/strong>&#8221; alternative to permanent stents, eliminating long-term complications associated with metallic implants<\/li>\n\n\n\n<li><strong>Clinical Target<\/strong>: Intracranial atherosclerotic disease (ICAD), a leading cause of stroke in Asian populations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The exclusive distribution agreement positions Peijia to address China&#8217;s substantial <strong>cerebrovascular disease burden<\/strong>, where <strong>intracranial atherosclerosis accounts for approximately 30\u201350% of ischemic strokes<\/strong> compared to 8\u201310% in Western populations:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity<\/strong>: China&#8217;s neurointerventional market projected to reach <strong>\u00a515\u201320 billion ($2.1\u20132.8 billion) annually by 2028<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: Limited treatment options for intracranial vascular disease, with current therapies carrying high restenosis rates<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: First drug-coated balloon specifically designed for intracranial applications in the Chinese market<\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong>: Potential to significantly reduce stroke recurrence rates and improve patient outcomes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This exclusive partnership with B. Braun represents a strategic expansion of our neurointerventional portfolio into innovative drug-delivery technologies,&#8221; said Dr. Li Chen, Chief Executive Officer of Peijia Medical. &#8220;SeQuent Please CIS addresses a critical gap in China&#8217;s stroke prevention landscape, offering neurointerventional specialists a sophisticated &#8216;no-implant&#8217; solution specifically designed for our patients&#8217; unique anatomical characteristics.&#8221;<\/p>\n\n\n\n<h2 id=\"h-commercial-outlook-amp-competitive-positioning\" class=\"wp-block-heading\">Commercial Outlook &amp; Competitive Positioning<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Peijia&#8217;s established commercial infrastructure provides immediate market access advantages:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Distribution Network<\/strong>: Leverages existing relationships with <strong>500+ neurointerventional centers<\/strong> across China<\/li>\n\n\n\n<li><strong>Physician Training<\/strong>: Comprehensive educational programs to support adoption of novel DCB technology<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Premium positioning reflecting clinical innovation and improved patient outcomes<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Benefits from China&#8217;s accelerated review processes for innovative medical devices addressing unmet needs<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts view the deal as transformative for Peijia, establishing the company as a leader in advanced cerebrovascular interventions while providing B. Braun with optimal market penetration through a specialized local partner.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding distribution agreements, regulatory approvals, and market opportunities for SeQuent Please CIS. Actual results may differ due to NMPA review outcomes, market adoption patterns, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100004_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060100004_c.\"><\/object><a id=\"wp-block-file--media-6464dfb7-852b-403a-b1f4-67219895f4f0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100004_c.pdf\">2026060100004_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100004_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6464dfb7-852b-403a-b1f4-67219895f4f0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1161,319],"class_list":["post-66963","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-9996","tag-peijia-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Peijia Medical Secures Exclusive China Distribution Rights for B. Braun&#039;s SeQuent Please CIS Intracranial Drug-Coated Balloon - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG for the SeQuent Please CIS, a paclitaxel drug-coated intracranial balloon dilatation catheter, in mainland China. The partnership grants Peijia exclusive rights to commercialize B. Braun&#039;s innovative &quot;no-implant&quot; therapy for intracranial vascular diseases, leveraging B. Braun&#039;s established drug-coated balloon (DCB) technology to address the significant unmet need in China&#039;s cerebrovascular intervention market. The product has been filed for marketing approval in China and is specifically engineered for the slender and tortuous anatomy of intracranial vessels.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66963\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun&#039;s SeQuent Please CIS Intracranial Drug-Coated Balloon\" \/>\n<meta property=\"og:description\" content=\"Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG for the SeQuent Please CIS, a paclitaxel drug-coated intracranial balloon dilatation catheter, in mainland China. The partnership grants Peijia exclusive rights to commercialize B. Braun&#039;s innovative &quot;no-implant&quot; therapy for intracranial vascular diseases, leveraging B. Braun&#039;s established drug-coated balloon (DCB) technology to address the significant unmet need in China&#039;s cerebrovascular intervention market. The product has been filed for marketing approval in China and is specifically engineered for the slender and tortuous anatomy of intracranial vessels.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66963\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T07:00:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T07:00:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66963#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66963\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun&#8217;s SeQuent Please CIS Intracranial Drug-Coated Balloon\",\"datePublished\":\"2026-06-01T07:00:26+00:00\",\"dateModified\":\"2026-06-01T07:00:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66963\"},\"wordCount\":524,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 9996\",\"Peijia Medical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66963#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66963\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66963\",\"name\":\"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun's SeQuent Please CIS Intracranial Drug-Coated Balloon - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T07:00:26+00:00\",\"dateModified\":\"2026-06-01T07:00:28+00:00\",\"description\":\"Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG for the SeQuent Please CIS, a paclitaxel drug-coated intracranial balloon dilatation catheter, in mainland China. The partnership grants Peijia exclusive rights to commercialize B. Braun's innovative \\\"no-implant\\\" therapy for intracranial vascular diseases, leveraging B. Braun's established drug-coated balloon (DCB) technology to address the significant unmet need in China's cerebrovascular intervention market. The product has been filed for marketing approval in China and is specifically engineered for the slender and tortuous anatomy of intracranial vessels.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66963#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66963\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66963#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun&#8217;s SeQuent Please CIS Intracranial Drug-Coated Balloon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun's SeQuent Please CIS Intracranial Drug-Coated Balloon - Insight, China&#039;s Pharmaceutical Industry","description":"Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG for the SeQuent Please CIS, a paclitaxel drug-coated intracranial balloon dilatation catheter, in mainland China. The partnership grants Peijia exclusive rights to commercialize B. Braun's innovative \"no-implant\" therapy for intracranial vascular diseases, leveraging B. Braun's established drug-coated balloon (DCB) technology to address the significant unmet need in China's cerebrovascular intervention market. The product has been filed for marketing approval in China and is specifically engineered for the slender and tortuous anatomy of intracranial vessels.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66963","og_locale":"en_US","og_type":"article","og_title":"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun's SeQuent Please CIS Intracranial Drug-Coated Balloon","og_description":"Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG for the SeQuent Please CIS, a paclitaxel drug-coated intracranial balloon dilatation catheter, in mainland China. The partnership grants Peijia exclusive rights to commercialize B. Braun's innovative \"no-implant\" therapy for intracranial vascular diseases, leveraging B. Braun's established drug-coated balloon (DCB) technology to address the significant unmet need in China's cerebrovascular intervention market. The product has been filed for marketing approval in China and is specifically engineered for the slender and tortuous anatomy of intracranial vessels.","og_url":"https:\/\/flcube.com\/?p=66963","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T07:00:26+00:00","article_modified_time":"2026-06-01T07:00:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66963#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66963"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun&#8217;s SeQuent Please CIS Intracranial Drug-Coated Balloon","datePublished":"2026-06-01T07:00:26+00:00","dateModified":"2026-06-01T07:00:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66963"},"wordCount":524,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 9996","Peijia Medical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66963#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66963","url":"https:\/\/flcube.com\/?p=66963","name":"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun's SeQuent Please CIS Intracranial Drug-Coated Balloon - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T07:00:26+00:00","dateModified":"2026-06-01T07:00:28+00:00","description":"Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG for the SeQuent Please CIS, a paclitaxel drug-coated intracranial balloon dilatation catheter, in mainland China. The partnership grants Peijia exclusive rights to commercialize B. Braun's innovative \"no-implant\" therapy for intracranial vascular diseases, leveraging B. Braun's established drug-coated balloon (DCB) technology to address the significant unmet need in China's cerebrovascular intervention market. The product has been filed for marketing approval in China and is specifically engineered for the slender and tortuous anatomy of intracranial vessels.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66963#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66963"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66963#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Peijia Medical Secures Exclusive China Distribution Rights for B. Braun&#8217;s SeQuent Please CIS Intracranial Drug-Coated Balloon"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66963"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66963\/revisions"}],"predecessor-version":[{"id":66965,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66963\/revisions\/66965"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}